# CBG Survey Finds Patient Interest Outpaces Clinical Proof > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-cbg-survey-finds-patient-interest-o-2026-10-05/ > **Published:** 2026-10-06T11:43:42-04:00 | **Last Modified / Clinically Audited:** 2026-10-06T11:43:42-04:00 > **Clinical Summary:** medical cannabis research: Physician review of A Survey of Cannabigerol User's Patterns of Use, Perceived Efficacy and Satisfaction.: evidence analysis, dosi... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of A Survey of Cannabigerol User's Patterns of Use, Perceived Efficacy and Satisfaction.. Clinical Insight | CED Clinic This survey is clinically useful because it describes how real CBG and CBGA consumers are already using these products: mostly for insomnia, inflammatory pain, anxiety, episodic pain, and neuropathic pain. Typical reported dosing was modest, around 10 to 12 mg of CBG, with perceived onset after oral use within 15 to 60 minutes and duration of 4 to 6 hours. The key clinical caution is that symptom improvement was self reported, not measured with validated endpoints in a controlled trial. Clinicians can use these data for nonjudgmental medication reconciliation, expectation setting, and safety screening, not as proof of efficacy. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: CBG Survey Finds Patient Interest Outpaces Clinica. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42741890/) Table of Contents - [CBG Survey Finds Patient Interest Outpaces Clinical Proof](#CBG_Survey_Finds_Patient_Interest_Outpaces_Clinical_Proof)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # CBG Survey Finds Patient Interest Outpaces Clinical Proof A 239 person survey suggests CBG and CBGA users commonly target sleep, pain, and anxiety, but the evidence remains patient reported and not yet clinically proven. What This Study Teaches Us This survey of 239 CBG or CBGA users found the most common use targets were insomnia or disturbed sleep at 62%, inflammatory chronic pain at 44%, anxiety at 33%, episodic pain at 29%, and neuropathic chronic pain at 28%. Typical reported CBG dose was 10 to 12 mg, with perceived oral onset in 15 to 60 minutes and perceived duration of 4 to 6 hours. Why This Matters These data help clinicians ask better questions about real world CBG use, especially around sleep, pain, anxiety, dosing, timing, and product quality. They also help researchers design trials that reflect how patients are already using CBG and CBGA. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceJournal of psychoactive drugsPublication Date2026Sep15Evidence LevelJournal ArticleFocus AreaCBG Survey Finds Patient Interest Outpaces Clinical ProofLead AuthorsErika T H Lutz, Dustin Sulak, Leigh Vinocur, Ethan B Russo et al.DOI10.1080/02791072.2026.2727651PMIDPMID: 42741890 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** CBG is the next cannabis compound that treats sleep problems, pain, and anxiety. **Primary Journal Data:** In a survey of 239 CBG or CBGA users, 62% reported use for insomnia or disturbed sleep, 44% for inflammatory chronic pain, 33% for anxiety, 29% for episodic pain, and 28% for neuropathic chronic pain. Users generally reported slight to substantial perceived symptom improvement, with typical CBG doses of 10 to 12 mg and perceived effects lasting 4 to 6 hours. **Dr. Caplan’s Clinical Verdict:** Promising patient experience, not proof of treatment effect. The survey helps identify common use patterns and candidate trial targets, but it cannot establish that CBG or CBGA caused symptom improvement. Primary Analysis | A Survey of Cannabigerol User’s Patterns **Study Overview:** Cannabigerol (CBG) and the acidic form of CBG (cannabigerolic acid, CBGA) are becoming increasingly more available and popular, with pre-clinical rodent research suggesting these compounds have an array of therapeutic effects. However, there have been few clinical trials or surveys examining their effects in humans. We conducted a survey of 239 CBG/CBGA users to assess the medical conditions they use CBG/CBGA to manage, as well as their perceived efficacy and satisfaction with CBG/CBGA for managing these conditions. Participants also reported on their typical use patterns (e.g. typical dose), their perceived time to feel effects, and duration of those effects. The top five conditions participants reported using CBG/CBGA to manage were insomnia/disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%), and neuropathic chronic pain (28%), with participants generally reporting that CBG/CBGA “slightly improves” to “much improves” their symptoms. Participants reported typically using a dose of 10-12 mg of CBG and they indicated that they feel effects within 15-60 min of oral ingestion and that these effects persist for 4-6 h. These findings will help inform consumers of CBG as well as researchers designing clinical trials to investigate the effects of CBG on humans in a more objective manner. **Primary Source & Scope:** Published in *Journal of psychoactive drugs* (2026Sep15) conducted by Erika T H Lutz, Dustin Sulak, Leigh Vinocur, Ethan B Russo et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42741890/) | **Primary Record:** DOI: 10.1080/02791072.2026.2727651 | PMID: 42741890 How Strong Is This Evidence? The study has value as a 239 participant human survey in an area where clinical data remain sparse. It provides concrete descriptive statistics about indications, dosing, onset, and duration, which are useful for hypothesis generation and trial planning. Its statistical strength is limited by the absence of randomization, blinding, a control group, and objective clinical endpoints. Where This Paper Deserves Skepticism Self selection bias is substantial because people willing to complete a CBG survey may be more engaged, satisfied, or motivated than the broader population of users. Recall bias, expectancy effects, variable product composition, unmeasured THC or CBD exposure, and unverified diagnoses could all influence reported benefit. The survey cannot determine causality or isolate CBG from CBGA or other coexisting product constituents. What This Paper Does Not Show This study does not prove that CBG or CBGA effectively treats insomnia, chronic pain, anxiety, neuropathic pain, or any diagnosable medical condition. It also does not establish approved indications, standardized dosing, product equivalence, long term safety, or regulatory permission for disease treatment claims. How This Fits With the Broader Clinical Conversation Clinical research into A Survey of Cannabigerol User’s Patterns of Use, P is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, A Survey of Cannabigerol User’s Patterns of Use, Perceived Efficacy and Satisfaction. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away CBG and CBGA deserve careful study, especially for sleep, pain, and anxiety, but current evidence remains survey based. Patients using these products should document dose, timing, effects, side effects, and product testing, then discuss them with a knowledgeable clinician. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[💢Pain](https://cedclinic.com/ask)[💤Sleep](https://cedclinic.com/ask)[🧠Anxiety and Mood](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding A Survey of Cannabigerol User’s Patterns of U requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Treat the percentages as reports from current users, not prevalence estimates for the general population or proof of response rates. **Critical Rule**Separate perceived symptom improvement from measured clinical efficacy because the study lacked placebo control, blinding, and validated outcome endpoints. **Critical Rule**Interpret the 10 to 12 mg dose and 4 to 6 hour duration as real world user reports that can guide research design, not as prescribing standards. Key Evaluation Question Do the survey methods allow a causal conclusion that CBG or CBGA improved sleep, pain, or anxiety, or do they only document perceived benefit among self selected users? The Patient Question If I am using or considering CBG, how should I track dose, timing, product label details, benefits, side effects, and interactions with my current medications? The Bottom Line This study shows that many CBG and CBGA users report perceived benefits for sleep, pain, and anxiety at modest doses, but it does not prove clinical efficacy or define safe standardized treatment. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis This study surveyed 239 people already using CBG or CBGA. The most common reasons were insomnia or disturbed sleep at 62%, inflammatory chronic pain at 44%, anxiety at 33%, episodic pain at 29%, and neuropathic chronic pain at 28%. Respondents generally described symptoms as slightly improved to much improved. The evidence is observational, self selected, and perception based. There was no placebo group, randomization, blinding, diagnostic confirmation, or objective sleep, pain, or anxiety measurement. The survey is best read as a map of consumer behavior, not as clinical validation. Lens takeawayThe survey identifies promising targets, but it does not prove therapeutic efficacy. #### Patient Communication For patient care, the most useful message is curiosity without overpromising. Many patients are already experimenting with CBG for sleep, pain, and anxiety, often outside medical supervision. Asking directly about CBG, CBGA, dose, product source, and timing can improve medication reconciliation. Patients should be told that perceived benefit is meaningful but not the same as proven benefit. Clinicians can validate lived experience while still checking for sedation, drug interactions, pregnancy concerns, psychiatric vulnerability, liver disease, and unsafe substitution for established care. Lens takeawayPatient reports deserve respect, while clinical claims still require controlled evidence. #### Dosing & Formulations Respondents reported typical CBG doses of about 10 to 12 mg. They perceived onset within 15 to 60 minutes after oral ingestion and effects lasting around 4 to 6 hours. Those timings resemble many oral cannabinoid products, although absorption can vary widely. The survey does not establish an optimal dose, ceiling dose, or therapeutic window. It also does not clarify product purity, CBGA content, THC contamination, CBD co-use, terpene profile, food effects, or whether divided dosing is preferable for sleep versus chronic pain. Lens takeawayReported dosing offers trial design clues, not a validated prescribing protocol. #### Safety & Side Effect Profile The summary emphasizes perceived efficacy and satisfaction more than adverse events, which limits safety interpretation. CBG products may be marketed as gentle or nonintoxicating, but real products can contain other cannabinoids, residual solvents, pesticides, heavy metals, or mislabeled THC. Clinicians should still screen for sleepiness, dizziness, gastrointestinal symptoms, mood changes, impairment, and interactions. Caution is especially important with sedatives, alcohol, anticoagulants, seizure medications, psychiatric medications, liver disease, pregnancy, and safety sensitive work or driving. Ongoing post-market surveillance, contaminant screening, and standardized adverse-event reporting remain critical safeguards for patient health. Lens takeawayNonintoxicating marketing should not replace structured safety and interaction screening. #### Regulatory & Policy Dynamics CBG and CBGA products are increasingly available before robust clinical evidence exists. That creates a familiar policy gap: consumers can buy products for medical reasons, while clinicians lack standardized labels, pharmacokinetic data, safety registries, or dosing guidance. Regulators and health systems should distinguish access from substantiation. This survey supports the need for quality testing, accurate cannabinoid labeling, adverse event reporting, and clinical trials. It does not justify disease treatment claims on product packaging. Consistent administrative oversight and clear statutory definitions ensure that public health protections keep pace with evolving consumer formulations. Lens takeawayAccess is expanding faster than labeling standards and clinical evidence. #### Mechanisms & Physiology Preclinical work has suggested that CBG and CBGA may influence inflammation, nociception, mood related signaling, and other pathways. These mechanisms are biologically plausible, but rodent and laboratory findings do not automatically translate into reliable human symptom improvement. The survey cannot identify mechanism. Improvements in sleep, pain, or anxiety could reflect pharmacology, expectancy, concurrent cannabinoid exposure, natural symptom fluctuation, regression to the mean, or lifestyle changes. Mechanistic claims need controlled studies with biomarkers and validated outcomes. Lens takeawayBiological plausibility supports research, but it does not confirm clinical action. #### Research Limitations The main limitations are self selection and self report. People who choose to answer a CBG survey may be more enthusiastic, more satisfied, or more experienced than average users. Conditions may not have been clinically diagnosed or measured with validated instruments. The study also cannot separate CBG from CBGA, other cannabinoids, terpenes, product quality, dose accuracy, or prior cannabis experience. Without a comparison group, placebo effects and normal symptom variation remain major alternative explanations. Readers should carefully evaluate cohort composition, potential confounding variables, and study duration before generalizing preliminary findings across broader clinical populations. Lens takeawayThe data are useful for hypothesis generation, not for definitive clinical conclusions. #### Future Outlook The strongest next step is controlled clinical testing in the conditions most commonly reported here: sleep disturbance, inflammatory pain, anxiety, episodic pain, and neuropathic pain. Trials should use verified products, fixed doses, safety monitoring, and validated endpoints. The reported 10 to 12 mg dose range and 4 to 6 hour perceived duration can help design early dose finding studies. Future research should compare CBG, CBGA, CBD, THC containing combinations, and placebo across meaningful patient subgroups. Lens takeawayThis survey provides a practical blueprint for the next controlled CBG trials. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CBG+Survey+Finds+Patient+Interest+Outpaces+Clinical+Proof&url=https%3A%2F%2Fcedclinic.com%2Fced-cbg-survey-finds-patient-interest-o-2026-10-05%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-cbg-survey-finds-patient-interest-o-2026-10-05%2F) [BlueSky](https://bsky.app/intent/compose?text=CBG+Survey+Finds+Patient+Interest+Outpaces+Clinical+Proof%20https%3A%2F%2Fcedclinic.com%2Fced-cbg-survey-finds-patient-interest-o-2026-10-05%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: A Survey of Cannabigerol User's Patterns of Use, Perceived Efficacy and Satisfaction.](https://pubmed.ncbi.nlm.nih.gov/42741890/) Related Reading at CED ClinicContinue exploring the evidence[Cannabinoids for Low Back Pain and Migraine: What Randomized Trials Actually Show](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) More on this topic: Rigorous physician appraisal of randomized trials investigating cannabinoid efficacy for chronic pain and migraines. [More on this topic: Chronic pain & migraine](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/) More on this topic: Direct comparison of THC and CBD analgesic pathways and evidence-supported clinical indications. [More on this topic: CBD vs THC for pain](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/) ## Frequently Asked Questions Does this study prove that CBG treats insomnia? No. Sixty two percent of respondents reported using CBG or CBGA for insomnia or disturbed sleep, and many perceived improvement, but the study was a survey without placebo control, objective sleep tracking, or randomization. What dose of CBG did users typically report? Participants typically reported using about 10 to 12 mg of CBG. This is a descriptive finding, not a medically established dose or a recommendation for every patient. How quickly did users say CBG worked? Respondents reported feeling effects within 15 to 60 minutes after oral ingestion. Actual onset may vary by product type, meal timing, metabolism, dose, and whether other cannabinoids were present. How long did users say the effects lasted? Users generally reported effects lasting about 4 to 6 hours. This perceived duration should be confirmed in pharmacokinetic and controlled clinical studies. Which conditions were most commonly targeted with CBG or CBGA? The top reported conditions were insomnia or disturbed sleep at 62%, inflammatory chronic pain at 44%, anxiety at 33%, episodic pain at 29%, and neuropathic chronic pain at 28%. Is CBG safer than THC? CBG is often described as nonintoxicating, but this survey does not prove comparative safety. Product contamination, mislabeled THC, drug interactions, sedation, and vulnerable patient factors still matter clinically. Can patients combine CBG with prescription medications? Patients should discuss CBG with a clinician or pharmacist before combining it with sedatives, alcohol, anticoagulants, seizure medicines, psychiatric medications, or drugs with liver metabolism concerns. Is CBGA the same as CBG? No. CBGA is the acidic precursor form of CBG. Products may contain one or both, and this survey does not establish whether one form is more effective or safer than the other. Should clinicians recommend CBG based on this paper? Clinicians should not treat this survey as proof of efficacy. It can support informed discussion, documentation of patient use, harm reduction counseling, and identification of conditions needing better clinical trials. What would stronger evidence look like? Stronger evidence would include randomized, placebo controlled trials using lab verified CBG or CBGA products, prespecified doses, validated symptom scales, adverse event monitoring, and adequate follow up. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).